Prothelia
Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficie...
Prothelia's Basic Information
Headquarters
Boston, Georgia, United States
Website
Founded Year
2008
Headcount
2 - 10
Prothelia's Competitors
HOLTON RENEWABLE POWER LTD
Genaxy Scientific Private Limited
New Delhi, India
Advanced Preservation Technologies
United States
Palo Alto Pet Hospital
Palo Alto, California,
MAVIDx, Inc
Employee Insights
Employee Function
Employee Location
Prothelia's Top Employees
Steven Axon
Chief Executive Officer
Enrique Diloné
Chief Technology Officer
Tristen Moors
Vice President, Clinical Operations
Cort Cramer
Senior Director, Nonclinical Development & Toxicology
Find Your Next Customer with Better Data
Get access to over 160 million contacts and companies' information in AroundDeal's B2B database, quickly build highly targeted prospect lists and directly reach the buying committee.
⭐Top-ranked on G2 Crowd
🛡️GDPR compliant•Cancel anytime
✨Free credits every month!
Frequently Asked Questions Regarding Prothelia
Where is Prothelia's headquarter located?
Prothelia's headquarter are located at United States.
How many employees does Prothelia have?
Prothelia has 2 - 10 employees.
What is Prothelia's official website?
Prothelia's official website is http://prothelia.com
What does Prothelia do?
Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficie...
Connect with anyone with AroundDeal today!
Whether you're looking to connect with key decision-makers or making remote or global hires, we've got you covered.
